Niox Group EV/FCF

What does Niox Group do? Circassia Group plc is a British biotechnology company specializing in the development of therapies for respiratory diseases. The company was founded in 2006 and is headquartered in Oxford. Circassia was founded by Steve Harris, who previously worked for the biopharmaceutical company Xenova Group plc. In its early years, the company focused on research and development of therapies for allergies and asthma. In 2014, Circassia went public on the London Stock Exchange. The company has developed an innovative business model that focuses on using its proprietary technology platform to identify novel therapy candidates. It works closely with pharmaceutical companies and other partners to accelerate the development of its therapy products and license its technology platform. Circassia's main focus is on developing therapies for respiratory diseases, particularly allergic asthma and chronic obstructive pulmonary disease (COPD). It has a range of products currently in various stages of clinical development. One of its leading products is NIOX VERO, a diagnostic device used to measure inflammation in the airways and improve the diagnosis of patients with asthma or COPD. Circassia also has a promising pipeline of therapy candidates, including Flutiform® (fluticasone propionate/formoterol fumarate), an inhaled medication for the treatment of asthma developed in collaboration with Japanese pharmaceutical company Kyorin. Additionally, the company has developed two novel drugs in the field of allergic rhinoconjunctivitis, one of which is currently being tested in phase III studies, while the other is nearing completion of phase II development. In conclusion, Circassia has established itself as an innovative biotechnology company focused on the development of therapies for respiratory diseases. It has a promising pipeline of therapy candidates at various stages of clinical development. The Circassia business model is based on utilizing its proprietary technology platform to identify and develop novel therapy candidates. Niox Group is one of the most popular companies on Eulerpool.